Four-year clinical update from the American Society of Breast Surgeons MammoSite brachytherapy trial

Jonathan C. Nelson; Peter D. Beitsch; Frank A. Vicini; Coral A. Quiet; Delia Garcia; Howard C. Snider; Mark A. Gittleman; Victor J. Zannis; Pat W. Whitworth; Richard E. Fine; Angela J. Keleher; Henry M. Kuerer

doi:10.1016/j.amjsurg.2008.09.016

Four-year clinical update from the American Society of Breast Surgeons MammoSite brachytherapy trial

Jonathan C. Nelson, Peter D. Beitsch, Frank A. Vicini, Coral A. Quiet, Delia Garcia, Howard C. Snider, Mark A. Gittleman, Victor J. Zannis, Pat W. Whitworth, Richard E. Fine, Angela J. Keleher, Henry M. Kuerer

Breast Surgical Oncology

Research output: Contribution to journal › Article › peer-review

63 Scopus citations

Abstract

Background: We present a 4-year update on the efficacy, cosmetic results, and complications of MammoSite breast brachytherapy in patients enrolled in the American Society of Breast Surgeons registry trial. Methods: A total of 1,449 breasts in 1,440 patients with early stage breast cancer undergoing breast-conserving therapy were treated with adjuvant, accelerated partial breast irradiation (APBI) (34 Gy in 3.4-Gy fractions) delivered with the MammoSite device. The median follow-up period for the entire group was 36.1 months. Results: The 3-year actuarial rate of ipsilateral breast tumor recurrence was 2.15%. The 3-year actuarial rate of axillary recurrence was .36%. Complication rates were as follows: infection, 9.5%; seroma, 26.8% (symptomatic seroma, 12.7%); and fat necrosis, 2.0%. The percentages of breasts with good or excellent cosmetic results were as follows: 12 months, 95%; 24 months, 94%; 36 months, 94%; and 48 months, 91%. Conclusions: Locoregional control, complications, and cosmetic outcomes from MammoSite APBI at the 4-year update are acceptable and similar to results seen with other forms of APBI.

Original language	English (US)
Pages (from-to)	83-91
Number of pages	9
Journal	American Journal of Surgery
Volume	198
Issue number	1
DOIs	https://doi.org/10.1016/j.amjsurg.2008.09.016
State	Published - Jul 2009

Keywords

Brachytherapy
Breast-conserving therapy
MammoSite
Partial breast irradiation
Radiation

ASJC Scopus subject areas

Surgery

Access to Document

10.1016/j.amjsurg.2008.09.016

Cite this

Nelson, J. C., Beitsch, P. D., Vicini, F. A., Quiet, C. A., Garcia, D., Snider, H. C., Gittleman, M. A., Zannis, V. J., Whitworth, P. W., Fine, R. E., Keleher, A. J., & Kuerer, H. M. (2009). Four-year clinical update from the American Society of Breast Surgeons MammoSite brachytherapy trial. American Journal of Surgery, 198(1), 83-91. https://doi.org/10.1016/j.amjsurg.2008.09.016

@article{3b2ca81760ce4656a2357b4008c4285b,

title = "Four-year clinical update from the American Society of Breast Surgeons MammoSite brachytherapy trial",

abstract = "Background: We present a 4-year update on the efficacy, cosmetic results, and complications of MammoSite breast brachytherapy in patients enrolled in the American Society of Breast Surgeons registry trial. Methods: A total of 1,449 breasts in 1,440 patients with early stage breast cancer undergoing breast-conserving therapy were treated with adjuvant, accelerated partial breast irradiation (APBI) (34 Gy in 3.4-Gy fractions) delivered with the MammoSite device. The median follow-up period for the entire group was 36.1 months. Results: The 3-year actuarial rate of ipsilateral breast tumor recurrence was 2.15%. The 3-year actuarial rate of axillary recurrence was .36%. Complication rates were as follows: infection, 9.5%; seroma, 26.8% (symptomatic seroma, 12.7%); and fat necrosis, 2.0%. The percentages of breasts with good or excellent cosmetic results were as follows: 12 months, 95%; 24 months, 94%; 36 months, 94%; and 48 months, 91%. Conclusions: Locoregional control, complications, and cosmetic outcomes from MammoSite APBI at the 4-year update are acceptable and similar to results seen with other forms of APBI.",

keywords = "Brachytherapy, Breast-conserving therapy, MammoSite, Partial breast irradiation, Radiation",

author = "Nelson, {Jonathan C.} and Beitsch, {Peter D.} and Vicini, {Frank A.} and Quiet, {Coral A.} and Delia Garcia and Snider, {Howard C.} and Gittleman, {Mark A.} and Zannis, {Victor J.} and Whitworth, {Pat W.} and Fine, {Richard E.} and Keleher, {Angela J.} and Kuerer, {Henry M.}",

year = "2009",

month = jul,

doi = "10.1016/j.amjsurg.2008.09.016",

language = "English (US)",

volume = "198",

pages = "83--91",

journal = "American Journal of Surgery",

issn = "0002-9610",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Four-year clinical update from the American Society of Breast Surgeons MammoSite brachytherapy trial

AU - Nelson, Jonathan C.

AU - Beitsch, Peter D.

AU - Vicini, Frank A.

AU - Quiet, Coral A.

AU - Garcia, Delia

AU - Snider, Howard C.

AU - Gittleman, Mark A.

AU - Zannis, Victor J.

AU - Whitworth, Pat W.

AU - Fine, Richard E.

AU - Keleher, Angela J.

AU - Kuerer, Henry M.

PY - 2009/7

Y1 - 2009/7

N2 - Background: We present a 4-year update on the efficacy, cosmetic results, and complications of MammoSite breast brachytherapy in patients enrolled in the American Society of Breast Surgeons registry trial. Methods: A total of 1,449 breasts in 1,440 patients with early stage breast cancer undergoing breast-conserving therapy were treated with adjuvant, accelerated partial breast irradiation (APBI) (34 Gy in 3.4-Gy fractions) delivered with the MammoSite device. The median follow-up period for the entire group was 36.1 months. Results: The 3-year actuarial rate of ipsilateral breast tumor recurrence was 2.15%. The 3-year actuarial rate of axillary recurrence was .36%. Complication rates were as follows: infection, 9.5%; seroma, 26.8% (symptomatic seroma, 12.7%); and fat necrosis, 2.0%. The percentages of breasts with good or excellent cosmetic results were as follows: 12 months, 95%; 24 months, 94%; 36 months, 94%; and 48 months, 91%. Conclusions: Locoregional control, complications, and cosmetic outcomes from MammoSite APBI at the 4-year update are acceptable and similar to results seen with other forms of APBI.

AB - Background: We present a 4-year update on the efficacy, cosmetic results, and complications of MammoSite breast brachytherapy in patients enrolled in the American Society of Breast Surgeons registry trial. Methods: A total of 1,449 breasts in 1,440 patients with early stage breast cancer undergoing breast-conserving therapy were treated with adjuvant, accelerated partial breast irradiation (APBI) (34 Gy in 3.4-Gy fractions) delivered with the MammoSite device. The median follow-up period for the entire group was 36.1 months. Results: The 3-year actuarial rate of ipsilateral breast tumor recurrence was 2.15%. The 3-year actuarial rate of axillary recurrence was .36%. Complication rates were as follows: infection, 9.5%; seroma, 26.8% (symptomatic seroma, 12.7%); and fat necrosis, 2.0%. The percentages of breasts with good or excellent cosmetic results were as follows: 12 months, 95%; 24 months, 94%; 36 months, 94%; and 48 months, 91%. Conclusions: Locoregional control, complications, and cosmetic outcomes from MammoSite APBI at the 4-year update are acceptable and similar to results seen with other forms of APBI.

KW - Brachytherapy

KW - Breast-conserving therapy

KW - MammoSite

KW - Partial breast irradiation

KW - Radiation

UR - http://www.scopus.com/inward/record.url?scp=67649612766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649612766&partnerID=8YFLogxK

U2 - 10.1016/j.amjsurg.2008.09.016

DO - 10.1016/j.amjsurg.2008.09.016

M3 - Article

C2 - 19268900

AN - SCOPUS:67649612766

SN - 0002-9610

VL - 198

SP - 83

EP - 91

JO - American Journal of Surgery

JF - American Journal of Surgery

IS - 1

ER -

Four-year clinical update from the American Society of Breast Surgeons MammoSite brachytherapy trial

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this